The intravenous injection of CD105-positive renal cell carcinoma-derived EVs enhances the expression of pro-angiogenic factors such as vascular endothelial growth factor (VEGF), matrix metalloproteinase-2 (MMP-2), and MMP-9 and activates angiogenic phenotypes in normal human endothelial cells, stimulating their growth and vessel formation in SCID mice (40). Here, MMP2 is linked to hereditary clear cell renal cell carcinoma.